American Century Companies’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$39.5M Sell
679,314
-1,159
-0.2% -$53.4K 0.02% 859
2025
Q4
$30.5M Buy
680,473
+21,216
+3% +$891K 0.02% 950
2025
Q3
$26.5M Sell
659,257
-20,600
-3% -$726K 0.01% 995
2025
Q2
$21.3M Buy
+679,857
New +$22.2M 0.01% 1062
2024
Q3
Sell
-5,979
Closed -$233K 2967
2024
Q2
$233K Sell
5,979
-3,676
-38% -$147K ﹤0.01% 2697
2024
Q1
$416K Buy
9,655
+2,456
+34% +$113K ﹤0.01% 2516
2023
Q4
$332K Buy
+7,199
New +$254K ﹤0.01% 2521
2023
Q2
Sell
-9,474
Closed -$337K 2850
2023
Q1
$337K Sell
9,474
-1,531
-14% -$56.6K ﹤0.01% 2265
2022
Q4
$434K Buy
11,005
+4,335
+65% +$158K ﹤0.01% 2093
2022
Q3
$241K Buy
+6,670
New +$240K ﹤0.01% 2178

Other funds holding XENE

American Century Companies's XENE Position: Q1 2026 in Review

American Century Companies reduced its Xenon Pharmaceuticals (XENE) stake by 0.17% in Q1 2026, selling an estimated $53.4K and leaving 679,314 shares worth $39.5M. The position accounts for 0.02% of the portfolio, ranked #859.

American Century Companies first reported a position in XENE in Q3 2022 and has held it in 10 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • American Century Companies held 679,314 shares of Xenon Pharmaceuticals worth $39.5M as of Q1 2026.
  • American Century Companies sold 1,159 Xenon Pharmaceuticals shares in Q1 2026, an estimated $53.4K.
  • Xenon Pharmaceuticals made up 0.02% of American Century Companies's portfolio in Q1 2026, its #859 holding.
  • American Century Companies first reported a position in Xenon Pharmaceuticals in Q3 2022 and has held it in 10 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.